Global Circulating Tumor DNA Diagnostics Supply, Demand and Key Producers, 2023-2029

Page: 104

Published Date: 23 Mar 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Circulating Tumor DNA Diagnostics market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Circulating Tumor DNA Diagnostics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Circulating Tumor DNA Diagnostics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Circulating Tumor DNA Diagnostics that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Circulating Tumor DNA Diagnostics total market, 2018-2029, (USD Million)
Global Circulating Tumor DNA Diagnostics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Circulating Tumor DNA Diagnostics total market, key domestic companies and share, (USD Million)
Global Circulating Tumor DNA Diagnostics revenue by player and market share 2018-2023, (USD Million)
Global Circulating Tumor DNA Diagnostics total market by Type, CAGR, 2018-2029, (USD Million)
Global Circulating Tumor DNA Diagnostics total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Circulating Tumor DNA Diagnostics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc. and CellMax Life, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Circulating Tumor DNA Diagnostics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Circulating Tumor DNA Diagnostics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Circulating Tumor DNA Diagnostics Market, Segmentation by Type
Test Kits
Reagents

Global Circulating Tumor DNA Diagnostics Market, Segmentation by Application
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes

Companies Profiled:
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life

Key Questions Answered
1. How big is the global Circulating Tumor DNA Diagnostics market?
2. What is the demand of the global Circulating Tumor DNA Diagnostics market?
3. What is the year over year growth of the global Circulating Tumor DNA Diagnostics market?
4. What is the total value of the global Circulating Tumor DNA Diagnostics market?
5. Who are the major players in the global Circulating Tumor DNA Diagnostics market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Circulating Tumor DNA Diagnostics Introduction
    1.2 World Circulating Tumor DNA Diagnostics Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Circulating Tumor DNA Diagnostics Total Market by Region (by Headquarter Location)
        1.3.1 World Circulating Tumor DNA Diagnostics Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Circulating Tumor DNA Diagnostics Market Size (2018-2029)
        1.3.3 China Circulating Tumor DNA Diagnostics Market Size (2018-2029)
        1.3.4 Europe Circulating Tumor DNA Diagnostics Market Size (2018-2029)
        1.3.5 Japan Circulating Tumor DNA Diagnostics Market Size (2018-2029)
        1.3.6 South Korea Circulating Tumor DNA Diagnostics Market Size (2018-2029)
        1.3.7 ASEAN Circulating Tumor DNA Diagnostics Market Size (2018-2029)
        1.3.8 India Circulating Tumor DNA Diagnostics Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Circulating Tumor DNA Diagnostics Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Circulating Tumor DNA Diagnostics Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.2 World Circulating Tumor DNA Diagnostics Consumption Value by Region
        2.2.1 World Circulating Tumor DNA Diagnostics Consumption Value by Region (2018-2023)
        2.2.2 World Circulating Tumor DNA Diagnostics Consumption Value Forecast by Region (2024-2029)
    2.3 United States Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.4 China Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.5 Europe Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.6 Japan Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.7 South Korea Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.8 ASEAN Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)
    2.9 India Circulating Tumor DNA Diagnostics Consumption Value (2018-2029)

3 World Circulating Tumor DNA Diagnostics Companies Competitive Analysis
    3.1 World Circulating Tumor DNA Diagnostics Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Circulating Tumor DNA Diagnostics Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Circulating Tumor DNA Diagnostics in 2022
        3.2.3 Global Concentration Ratios (CR8) for Circulating Tumor DNA Diagnostics in 2022
    3.3 Circulating Tumor DNA Diagnostics Company Evaluation Quadrant
    3.4 Circulating Tumor DNA Diagnostics Market: Overall Company Footprint Analysis
        3.4.1 Circulating Tumor DNA Diagnostics Market: Region Footprint
        3.4.2 Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
        3.4.3 Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Circulating Tumor DNA Diagnostics Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Circulating Tumor DNA Diagnostics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Circulating Tumor DNA Diagnostics Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Circulating Tumor DNA Diagnostics Consumption Value Comparison
        4.2.1 United States VS China: Circulating Tumor DNA Diagnostics Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Circulating Tumor DNA Diagnostics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Circulating Tumor DNA Diagnostics Companies and Market Share, 2018-2023
        4.3.1 United States Based Circulating Tumor DNA Diagnostics Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Circulating Tumor DNA Diagnostics Revenue, (2018-2023)
    4.4 China Based Companies Circulating Tumor DNA Diagnostics Revenue and Market Share, 2018-2023
        4.4.1 China Based Circulating Tumor DNA Diagnostics Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Circulating Tumor DNA Diagnostics Revenue, (2018-2023)
    4.5 Rest of World Based Circulating Tumor DNA Diagnostics Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Circulating Tumor DNA Diagnostics Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Circulating Tumor DNA Diagnostics Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Circulating Tumor DNA Diagnostics Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Test Kits
        5.2.2 Reagents
    5.3 Market Segment by Type
        5.3.1 World Circulating Tumor DNA Diagnostics Market Size by Type (2018-2023)
        5.3.2 World Circulating Tumor DNA Diagnostics Market Size by Type (2024-2029)
        5.3.3 World Circulating Tumor DNA Diagnostics Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Circulating Tumor DNA Diagnostics Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospitals
        6.2.2 Diagnostics Laboratories
        6.2.3 Research Laboratories
        6.2.4 Academic Research Institutes
        6.2.5 Academic Research Institutes
    6.3 Market Segment by Application
        6.3.1 World Circulating Tumor DNA Diagnostics Market Size by Application (2018-2023)
        6.3.2 World Circulating Tumor DNA Diagnostics Market Size by Application (2024-2029)
        6.3.3 World Circulating Tumor DNA Diagnostics Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Grail, Inc.
        7.1.1 Grail, Inc. Details
        7.1.2 Grail, Inc. Major Business
        7.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Product and Services
        7.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Grail, Inc. Recent Developments/Updates
        7.1.6 Grail, Inc. Competitive Strengths & Weaknesses
    7.2 Guardant Health, Inc.
        7.2.1 Guardant Health, Inc. Details
        7.2.2 Guardant Health, Inc. Major Business
        7.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Services
        7.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Guardant Health, Inc. Recent Developments/Updates
        7.2.6 Guardant Health, Inc. Competitive Strengths & Weaknesses
    7.3 Biodesix, Inc.
        7.3.1 Biodesix, Inc. Details
        7.3.2 Biodesix, Inc. Major Business
        7.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Services
        7.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Biodesix, Inc. Recent Developments/Updates
        7.3.6 Biodesix, Inc. Competitive Strengths & Weaknesses
    7.4 Exosome Diagnostics
        7.4.1 Exosome Diagnostics Details
        7.4.2 Exosome Diagnostics Major Business
        7.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Services
        7.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Exosome Diagnostics Recent Developments/Updates
        7.4.6 Exosome Diagnostics Competitive Strengths & Weaknesses
    7.5 Freenome Inc.
        7.5.1 Freenome Inc. Details
        7.5.2 Freenome Inc. Major Business
        7.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Product and Services
        7.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Freenome Inc. Recent Developments/Updates
        7.5.6 Freenome Inc. Competitive Strengths & Weaknesses
    7.6 LungLife AI, Inc.
        7.6.1 LungLife AI, Inc. Details
        7.6.2 LungLife AI, Inc. Major Business
        7.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Services
        7.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 LungLife AI, Inc. Recent Developments/Updates
        7.6.6 LungLife AI, Inc. Competitive Strengths & Weaknesses
    7.7 Inivata Ltd.
        7.7.1 Inivata Ltd. Details
        7.7.2 Inivata Ltd. Major Business
        7.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Services
        7.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Inivata Ltd. Recent Developments/Updates
        7.7.6 Inivata Ltd. Competitive Strengths & Weaknesses
    7.8 Personal Genome Diagnostics, Inc.
        7.8.1 Personal Genome Diagnostics, Inc. Details
        7.8.2 Personal Genome Diagnostics, Inc. Major Business
        7.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Services
        7.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Personal Genome Diagnostics, Inc. Recent Developments/Updates
        7.8.6 Personal Genome Diagnostics, Inc. Competitive Strengths & Weaknesses
    7.9 CellMax Life
        7.9.1 CellMax Life Details
        7.9.2 CellMax Life Major Business
        7.9.3 CellMax Life Circulating Tumor DNA Diagnostics Product and Services
        7.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 CellMax Life Recent Developments/Updates
        7.9.6 CellMax Life Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Circulating Tumor DNA Diagnostics Industry Chain
    8.2 Circulating Tumor DNA Diagnostics Upstream Analysis
    8.3 Circulating Tumor DNA Diagnostics Midstream Analysis
    8.4 Circulating Tumor DNA Diagnostics Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Circulating Tumor DNA Diagnostics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Circulating Tumor DNA Diagnostics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Circulating Tumor DNA Diagnostics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Circulating Tumor DNA Diagnostics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Circulating Tumor DNA Diagnostics Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Circulating Tumor DNA Diagnostics Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Circulating Tumor DNA Diagnostics Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Circulating Tumor DNA Diagnostics Players in 2022
    Table 12. World Circulating Tumor DNA Diagnostics Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Circulating Tumor DNA Diagnostics Company Evaluation Quadrant
    Table 14. Head Office of Key Circulating Tumor DNA Diagnostics Player
    Table 15. Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
    Table 16. Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
    Table 17. Circulating Tumor DNA Diagnostics Mergers & Acquisitions Activity
    Table 18. United States VS China Circulating Tumor DNA Diagnostics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Circulating Tumor DNA Diagnostics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Circulating Tumor DNA Diagnostics Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Circulating Tumor DNA Diagnostics Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Circulating Tumor DNA Diagnostics Revenue Market Share (2018-2023)
    Table 23. China Based Circulating Tumor DNA Diagnostics Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Circulating Tumor DNA Diagnostics Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Circulating Tumor DNA Diagnostics Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Circulating Tumor DNA Diagnostics Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Circulating Tumor DNA Diagnostics Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Circulating Tumor DNA Diagnostics Revenue Market Share (2018-2023)
    Table 29. World Circulating Tumor DNA Diagnostics Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Circulating Tumor DNA Diagnostics Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Circulating Tumor DNA Diagnostics Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Circulating Tumor DNA Diagnostics Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Circulating Tumor DNA Diagnostics Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Circulating Tumor DNA Diagnostics Market Size by Application (2024-2029) & (USD Million)
    Table 35. Grail, Inc. Basic Information, Area Served and Competitors
    Table 36. Grail, Inc. Major Business
    Table 37. Grail, Inc. Circulating Tumor DNA Diagnostics Product and Services
    Table 38. Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Grail, Inc. Recent Developments/Updates
    Table 40. Grail, Inc. Competitive Strengths & Weaknesses
    Table 41. Guardant Health, Inc. Basic Information, Area Served and Competitors
    Table 42. Guardant Health, Inc. Major Business
    Table 43. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Services
    Table 44. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Guardant Health, Inc. Recent Developments/Updates
    Table 46. Guardant Health, Inc. Competitive Strengths & Weaknesses
    Table 47. Biodesix, Inc. Basic Information, Area Served and Competitors
    Table 48. Biodesix, Inc. Major Business
    Table 49. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Services
    Table 50. Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Biodesix, Inc. Recent Developments/Updates
    Table 52. Biodesix, Inc. Competitive Strengths & Weaknesses
    Table 53. Exosome Diagnostics Basic Information, Area Served and Competitors
    Table 54. Exosome Diagnostics Major Business
    Table 55. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Services
    Table 56. Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Exosome Diagnostics Recent Developments/Updates
    Table 58. Exosome Diagnostics Competitive Strengths & Weaknesses
    Table 59. Freenome Inc. Basic Information, Area Served and Competitors
    Table 60. Freenome Inc. Major Business
    Table 61. Freenome Inc. Circulating Tumor DNA Diagnostics Product and Services
    Table 62. Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Freenome Inc. Recent Developments/Updates
    Table 64. Freenome Inc. Competitive Strengths & Weaknesses
    Table 65. LungLife AI, Inc. Basic Information, Area Served and Competitors
    Table 66. LungLife AI, Inc. Major Business
    Table 67. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Services
    Table 68. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. LungLife AI, Inc. Recent Developments/Updates
    Table 70. LungLife AI, Inc. Competitive Strengths & Weaknesses
    Table 71. Inivata Ltd. Basic Information, Area Served and Competitors
    Table 72. Inivata Ltd. Major Business
    Table 73. Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Services
    Table 74. Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Inivata Ltd. Recent Developments/Updates
    Table 76. Inivata Ltd. Competitive Strengths & Weaknesses
    Table 77. Personal Genome Diagnostics, Inc. Basic Information, Area Served and Competitors
    Table 78. Personal Genome Diagnostics, Inc. Major Business
    Table 79. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Services
    Table 80. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Personal Genome Diagnostics, Inc. Recent Developments/Updates
    Table 82. CellMax Life Basic Information, Area Served and Competitors
    Table 83. CellMax Life Major Business
    Table 84. CellMax Life Circulating Tumor DNA Diagnostics Product and Services
    Table 85. CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 86. Global Key Players of Circulating Tumor DNA Diagnostics Upstream (Raw Materials)
    Table 87. Circulating Tumor DNA Diagnostics Typical Customers
List of Figure
    Figure 1. Circulating Tumor DNA Diagnostics Picture
    Figure 2. World Circulating Tumor DNA Diagnostics Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Circulating Tumor DNA Diagnostics Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Circulating Tumor DNA Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 13. Circulating Tumor DNA Diagnostics Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Circulating Tumor DNA Diagnostics by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Circulating Tumor DNA Diagnostics Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Circulating Tumor DNA Diagnostics Markets in 2022
    Figure 27. United States VS China: Circulating Tumor DNA Diagnostics Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Circulating Tumor DNA Diagnostics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Circulating Tumor DNA Diagnostics Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Circulating Tumor DNA Diagnostics Market Size Market Share by Type in 2022
    Figure 31. Test Kits
    Figure 32. Reagents
    Figure 33. World Circulating Tumor DNA Diagnostics Market Size Market Share by Type (2018-2029)
    Figure 34. World Circulating Tumor DNA Diagnostics Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 35. World Circulating Tumor DNA Diagnostics Market Size Market Share by Application in 2022
    Figure 36. Hospitals
    Figure 37. Diagnostics Laboratories
    Figure 38. Research Laboratories
    Figure 39. Academic Research Institutes
    Figure 40. Circulating Tumor DNA Diagnostics Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Circulating Tumor DNA Diagnostics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Circulating Tumor DNA Diagnostics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

date 12 Aug 2022

date Medical Care

The Circulating Tumor DNA Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 27 Feb 2023

date Medical Care

According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Circulating Tumor DNA Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Circulating Tumor DNA Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 26 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD 13180 million in 2023 and is forecast to a readjusted size of USD 18990 million by 2030 with a CAGR of 5.4% during review period.

Product Tags

circulating tumor dna diagnostics

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>